ReviewInflammation and regeneration2020
Glioma progression and recurrence involving maintenance and expansion strategies of glioma stem cells by organizing self-advantageous niche microenvironments.
Review in Inflammation and regeneration, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- The cytoskeletal regulator Coronin-1A plays a multidirectional role in glioblastoma stemness.Scientific reports · 2026Article
- Beyond Resection: Surgery as an Evolutionary Bottleneck Shaping Tumor Evolution and Treatment Response in Diffuse Gliomas.Cancers · 2026Review
- Identification of PDLIM1 as a glioblastoma stem cell marker driving tumorigenesis and chemoresistance.Cell death discovery · 2024Article
- PBI-05204, a supercritical CONeoplasia (New York, N.Y.) · 2024Article
- Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements.Cancer biomarkers : section A of Disease markers · 2024Review
- GAS5 attenuates the malignant progression of glioma stem-like cells by promoting E-cadherin.Cancer gene therapy · 2023Article
- Targeting Options of Tumor-Associated Macrophages (TAM) Activity in Gliomas.Current neuropharmacology · 2023Review
- Transcription factor ZBTB42 is a novel prognostic factor associated with immune cell infiltration in glioma.Frontiers in pharmacology · 2023Article
- Interferon-beta inhibits human glioma stem cell growth by modulating immune response and cell cycle related signaling pathways.Cell regeneration (London, England) · 2022Article
- Global research trends and hotspots on glioma stem cells.Frontiers in oncology · 2022Article
- Emerging roles of ferroptosis in glioma.Frontiers in oncology · 2022Review
- Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma.Frontiers in oncology · 2022Article
- Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Role of Purinome, A Complex Signaling System, In Glioblastoma Aggressiveness.Frontiers in pharmacology · 2021Article
- Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.Frontiers in oncology · 2021Article
- A Fast and Efficient Approach to Obtaining High-Purity Glioma Stem Cell Culture.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the nature of enhanced resistance to conventional chemo/radiotherapies and metastasis, highly tumorigenic cancer stem cells (CSCs) have been proposed as a promising target for cancer eradication. To tackle the therapeutic difficulties of cancers involving CSCs, extensive research efforts have been directed toward understanding the extracellular microenvironments of CSCs, i.e., CSC niche, which plays important roles in CSC maintenance and expansion. Here we review recently identified mechanisms of maintenance and expansion of glioma CSCs (GSCs) leading to glioma progression and recurrence, with particular emphasis on the reports made by studies with a unique approach using polymer microarrays screening and with a unique viewpoint of necrotic particles. The polymer-based approach identified two groups of niche components, extracellular matrices (ECMs) and iron, and uncovered that co-expression of ECM-, iron-, and macrophage-related genes is predictive of glioma patients' outcome. The study in view of a unique fraction of GSC-derived necrotic particles proposed that such particles develop GSC-supportive tumor-associated macrophages (TAMs). Taken together, these studies provide new insights into the mechanisms underlying GSC-driven niche development, i.e., organization of the self-advantageous niche microenvironments for GSC maintenance and expansion leading to glioma progression and recurrence. A series of such studies can redefine the current concept of anti-GSC niche therapy that targets ligands/receptors supporting GSCs, and have potential to accelerate cancer therapy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.